Synthesised by Eli Lilly and Company in 1968, Memantine is one of the few pharmaceuticals approved by FDA for treatment of moderate-to-severe Alzheimer’s disease. Off-label use of Memantine also includes reversing tolerance for caffeine, nicotine and opioids; it might also be taken for a treatment of generalised anxiety disorder.

In the body Memantine reduces certain types of brain activity by binding to NMDA receptors and blocking the activity of glutamate. As a result, Memantine upregulates receptors in the brain and has a cognitive-enhancing effect.

Country of Manufacture: Russia